drugset / Trial / NCT00445315

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

NCT00445315

Phase 1 Completed 32 enrolled Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers

Timeline

Start
2007-01
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Filibuvir Small molecule 100 mg Oral
Subject Filibuvir Small molecule 300 mg Oral
Subject Filibuvir Small molecule 450 mg Oral